stockrowAzitra, Inc.
AZTR Healthcare Biotechnology
Azitra, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7,500.00, down 98.9% from fiscal 2023.
- EPS
- +85.3%
- Free cash flow
- −19.6%
Quarter to June 2026, against a year earlier
Follow AZTR
Alert me
Azitra, Inc. (AZTR) EV/Sales
As of 6 November 2026, Azitra, Inc. (AZTR) trades at a EV/Sales of −9.1×. Over the past ten years it has ranged from −12.9× (June 2026) to 28.6× (November 2023); the current reading is higher than 9% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | −5.0× | — |
| FY2023 | 8.1× | (70.98%) |
| FY2022 | 28.0× | 0.00% |
| FY2021 | 28.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2024 | 4.3× | (47.48%) |
| Dec 2023 | 8.1× | — |
| Sep 2023 | −3.9× | — |
| Jun 2023 | 5.7× | (79.50%) |
| 4 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CELZ Creative Medical Technology Holdings, Inc. compare | −378× |
| AZTR Azitra, Inc. | −9.1× |
| XBIO Xenetic Biosciences, Inc. compare | −0.3× |
| NCNA NuCana PLC Sponsored ADR compare | n/m |
| PMCB Nuvilex Inc. compare | n/m |
| NIKI Niki BioSolutions, Inc. compare | 1.3× |
| SKYE Skye Bioscience, Inc. compare | 3.6× |
| OSRH OSR Health, Inc. compare | 4.9× |
| ADTX Aditxt, Inc. compare | 73.3× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)